Vivani Medical publishes investor presentation on NanoPortal long-acting GLP-1 implant strategy for obesity market

Vivani Medical Inc.

VANI

0.00

Vivani outlined its NanoPortal ultra long-acting, removable subdermal GLP-1 implant platform targeting once- or twice-yearly dosing.
Lead candidate NPM-139, a semaglutide implant for chronic weight management, is slated to start its clinical program in mid-2026.
LIBERATE-1 first-in-human data met primary objectives on safety, tolerability, device performance, pharmacokinetics; no serious adverse events reported.
Global GLP-1 market cited at USD 132 billion in 2025 sales; Morgan Stanley estimate cited at about USD 190 billion by 2035.
Cash runway expected to fund the current operating plan through 1H2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.